LY 293111 (LY293111)

06/01/2007 - "In conclusion, LY293111 induces apoptosis in human pancreatic cancer cells through the mitochondria-mediated pathway. "
06/01/2005 - "A novel anti-pancreatic cancer agent, LY293111."
01/01/2008 - "LY293111 was shown to have potent anticancer effects in pancreatic cancer and several other solid malignancies, where it caused cell cycle arrest and marked apoptosis. "
06/01/2005 - "This review summarizes the current research status of LY293111 as an anti-cancer agent with a focus on pancreatic cancer."
04/01/2005 - "LY293111 is a novel therapeutic agent for pancreatic cancer, which improves the efficacy of gemcitabine. "

10/01/2002 - "In studies using AsPC-1 and HPAC cell xenografts in athymic mice, LY293111 treatment markedly inhibited tumor growth over a 24-day treatment period, as measured by both tumor volume and tumor weight. "
10/01/2004 - "As the toxicity of LY 293111 in man is not hematological, this agent may have a role in combination therapy of selected malignancies."
01/01/2008 - "LY293111 was shown to have potent anticancer effects in pancreatic cancer and several other solid malignancies, where it caused cell cycle arrest and marked apoptosis. "
06/01/2005 - "This review summarizes the current research status of LY293111 as an anti-cancer agent with a focus on pancreatic cancer."
08/10/2005 - "Phase I and pharmacokinetic study of LY293111, an orally bioavailable LTB4 receptor antagonist, in patients with advanced solid tumors."

09/01/1998 - "Although not statistically significant, a tendency for the increased expression of some markers of cutaneous inflammation and epidermal proliferation was observed after 1 week of treatment with VML295, and a decreased expression of these markers was seen after 4 weeks of treatment with VML295. "
04/04/1997 - "LY293111 proved to be a potent inhibitor of LTB4-induced cutaneous inflammation and hyperproliferation. "
12/01/1996 - "The effect of the novel LTB4 receptor antagonist, LY293111, was examined using allergen challenge as a model for asthmatic inflammation in 12 atopic asthmatic subjects in a double blind placebo controlled crossover trial. "

09/01/1998 - "VML295 in the treatment of chronic plaque psoriasis was shown to be safe and well tolerated. "
09/01/1998 - "The aim of the present study was to investigate the efficacy and clinical tolerability of the specific leukotriene B4 receptor antagonist VML295 in the treatment of stable plaque psoriasis. "

04/01/2005 - "The present study determined the effect of the LTB4 receptor antagonist, LY293111, on tumor growth and metastases in a fluorescent orthotopic model of pancreatic cancer. "